HealthcareServices

Monkey Pox Treatment Market Performance Outlook 2026–2030: Revenue to Hit $0.18 Billion at 13% CAGR

February 26, 2026March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the monkey pox treatment market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Monkey Pox Treatment Market’s size between 2026 and 2030?

The monkey pox treatment market size has seen swift expansion in recent years. It is anticipated to increase from $0.1 billion in 2025 to $0.11 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.0%. The market’s growth during previous periods can be linked to prior outbreaks in regions where the disease is endemic, restricted access to vaccines, delayed detection due to insufficient awareness, reliance on supportive medical care, and its worldwide dissemination during the 2022 outbreak.

The market for monkeypox treatments is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $0.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. Key factors contributing to this anticipated growth include the broadening of the antiviral drug pipeline, escalating global vaccination efforts, a boost in financial support for research into infectious diseases, the implementation of better diagnostic methods, and the development of government readiness programs. Significant trends expected during this forecast timeframe encompass the advancement of precision-focused antiviral therapies, the integration of AI-driven models for predicting outbreaks, the proliferation of digital tracking systems for overseeing cases, wider deployment of IoT-enabled networks for disease surveillance, and an increasing need for environmentally sound vaccine manufacturing techniques.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18818&type=smp

Which Drivers Are Shaping Strategic Decisions In The Monkey Pox Treatment Market?

The growing occurrence of zoonotic infections is anticipated to boost the expansion of the monkeypox treatment market in the future. Such an infection refers to an illness passed from animals to humans via direct contact with affected environments or carriers. Greater interaction between humans and animals, leading to closer proximity, escalates the risks of zoonotic infections. Furthermore, climate change exacerbates this danger by broadening the habitats of disease vectors and introducing harmful pathogens to previously unaffected regions. Monkeypox treatments are employed to manage zoonotic mpox, working by targeting the virus and easing symptoms in both people and potentially afflicted animals. For example, a report from the UK Health Security Agency, a government body in the UK, indicated 3,732 confirmed mpox cases in the UK by August 2024, following a rise of 21 cases in 2023 to a total of 3753 cases. Consequently, the rising prevalence of zoonotic infection is a key driver for the monkeypox treatment market.

What Segment Classifications Make Up The Monkey Pox Treatment Market?

The monkey pox treatment market covered in this report is segmented –

1) By Treatment Type: Prophylactic Vaccines, Therapeutics

2) By Dosage Forms: Solid, Liquid, Semi Solid

3) By Route Of Administration: Oral, Topical, Parenteral

4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Prophylactic Vaccines: Vaccinia-Based Vaccines, Modified Vaccinia Ankara (MVA) Vaccines

2) By Therapeutics: Antiviral Agents (Tecovirimat, Brincidofovir), Immune Modulators, Supportive Care Treatments

What Upcoming Trends Are Likely To Define The Future Path Of The Monkey Pox Treatment Market?

Leading companies within the monkeypox treatment market are concentrating on the creation of innovative products, such as small-molecule antivirals, to bolster global health preparedness and expand stockpiling capacity. These small-molecule antivirals function by impeding specific viral proteins, thereby halting the spread of the virus inside the body. Their suitability for long-term storage also makes them ideal for emergency responses. For instance, in January 2025, SIGA Technologies, a US-based pharmaceutical company, obtained approval in Japan for TEPOXX (tecovirimat 200 mg capsules), signifying the first antiviral approved in that nation for treating orthopoxviruses. This product exhibits a robust safety profile, backed by data from 15 clinical trials involving over 800 healthy volunteers. It also demonstrated measurable pharmacokinetics within effective dose ranges and showed strong preclinical efficacy in animal models, where it successfully reduced both mortality and viral load. The drug’s mechanism involves inhibiting the VP37 protein on the virus surface, which prevents the virus from exiting infected cells and thus allows the immune system to clear the infection. SIGA has collaborated with Japan Biotechno Pharma, designating them as its exclusive distributor, to aid in building Japan’s strategic national reserve of TEPOXX.

Which Key Market Players Are Investing In Expansion And Innovation Within The Monkey Pox Treatment Market?

Major companies operating in the monkey pox treatment market are Merck & Co Inc, Sanofi S A, Gilead Sciences Inc, BioNTech SE, Moderna Inc, Novavax Inc, Emergent BioSolutions Inc, Bavarian Nordic A S, SIGA Technologies Inc, Tonix Pharmaceuticals Holding Corp, Chimerix Inc, Emcure Pharmaceuticals Ltd, VBI Vaccines Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, GeoVax Labs Inc, Zydus Cadila Ltd, Serum Institute of India Pvt Ltd, Biological E Ltd, Dr Reddy’s Laboratories Ltd, Hester Bioscience Ltd, Indian Immunologicals Ltd, Reliance Life Sciences Pvt Ltd, Takeda Pharmaceuticals Co Ltd, KM Biologics Co Ltd, Meridian Bioscience Inc, NanoViricides Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/monkey-pox-treatment-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Monkey Pox Treatment Market?

North America was the largest region in the monkey pox treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monkey pox treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Monkey Pox Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18818&type=smp

Browse Through More Reports Similar to the Global Monkey Pox Treatment Market 2026, By The Business Research Company

Sheep And Goat Pox Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/sheep-and-goat-pox-vaccines-global-market-report

Monkey Pox Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/monkey-pox-testing-global-market-report

Zoonotic Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/zoonotic-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795